<DOC>
	<DOC>NCT02405793</DOC>
	<brief_summary>The purpose of this study is to evaluate the safety and efficacy of a low dose and a high dose of Meloxicam SoluMatrix® Capsules versus Meloxicam Tablets for the treatment of pain due to osteoarthritis of the knee or hip.</brief_summary>
	<brief_title>Meloxicam SoluMatrix® Capsules vs Meloxicam Tablets to Treat Osteoarthritis Pain</brief_title>
	<detailed_description />
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Meloxicam</mesh_term>
	<criteria>Primary diagnosis of Functional Class IIII osteoarthritis (OA) of the hip or knee Chronic user of nonsteroidal antiinflammatory drugs (NSAIDs) and/or acetaminophen for OA pain Discontinued all analgesic therapy at Screening For women of childbearing potential: a woman who is not pregnant and not nursing, and who is practicing an acceptable method of birth control Ability to ambulate History of allergic reaction or clinically significant intolerance to acetaminophen, aspirin, or any NSAIDs, including meloxicam Requires regular (more than 2 doses per week) use of opioid or opioid combination products to control OA pain of the knee or hip Clinically significant unstable cardiac, respiratory, neurological, immunological, hematological, or renal disease Significant difficulties swallowing capsules/tablets or unable to tolerate oral medication Previous participation in another clinical study of Meloxicam Capsules or received any investigational drug or device or investigational therapy within 30 days before Screening</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
</DOC>